lurasidone has been researched along with aripiprazole in 3 studies
| Studies (lurasidone) | Trials (lurasidone) | Recent Studies (post-2010) (lurasidone) | Studies (aripiprazole) | Trials (aripiprazole) | Recent Studies (post-2010) (aripiprazole) |
|---|---|---|---|---|---|
| 6 | 0 | 3 | 2,989 | 509 | 1,788 |
| Protein | Taxonomy | lurasidone (IC50) | aripiprazole (IC50) |
|---|---|---|---|
| ATP-dependent translocase ABCB1 | Homo sapiens (human) | 0.78 | |
| D(2) dopamine receptor | Homo sapiens (human) | 0.0158 | |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | 1.945 | |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | 1.38 | |
| Alpha-1A adrenergic receptor | Homo sapiens (human) | 0.17 | |
| Histamine H1 receptor | Homo sapiens (human) | 0.42 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 1.8572 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Azmanova, M; Barry, NPE; Pitto-Barry, A | 1 |
| Altamura, C; Arzuaga, A; Ciranna, L; Costa, L; Desaphy, JF; Lacivita, E; Leopoldo, M; Niso, M; Ragozzino, ME; Stama, ML | 1 |
| Ablordeppey, SY; Bloom, SH; Bricker, B; Eshleman, AJ; Gonela, UM; Janowsky, AJ; Ofori, E; Onyameh, EK; Schmachtenberg, JL; Swanson, TL; Voshavar, C | 1 |
1 review(s) available for lurasidone and aripiprazole
| Article | Year |
|---|---|
Schizophrenia: synthetic strategies and recent advances in drug design.
Topics: | 2018 |
2 other study(ies) available for lurasidone and aripiprazole
| Article | Year |
|---|---|
Privileged scaffold-based design to identify a novel drug-like 5-HT
Topics: Dose-Response Relationship, Drug; Drug Design; Fragile X Syndrome; HEK293 Cells; Humans; Molecular Structure; Piperazines; Receptors, Serotonin; Serotonin Receptor Agonists; Structure-Activity Relationship | 2020 |
New dual 5-HT1A and 5-HT7 receptor ligands derived from SYA16263.
Topics: Dose-Response Relationship, Drug; Humans; Ligands; Molecular Structure; Piperazines; Pyridines; Receptor, Serotonin, 5-HT1A; Receptors, Serotonin; Serotonin 5-HT1 Receptor Agonists; Serotonin Antagonists; Structure-Activity Relationship | 2021 |